LKH Feldkirch Intern E at LKH Rankweil
- Address
- Valdunastr. 16, 6830 Rankweil, Austria
LKH Feldkirch Intern E - Thoracic Oncology Research Center
LKH Feldkirch Intern E at LKH Rankweil is a specialized medical research facility dedicated to advancing the treatment of thoracic malignancies. The center focuses on innovative therapeutic approaches combining immunotherapy, chemotherapy, and surgical interventions for patients with lung cancer.
- Perioperative immunotherapy trials for resectable non-small cell lung cancer
- Novel combination therapies using immune checkpoint inhibitors with chemotherapy
- Pathologic complete response assessment in early-stage thoracic malignancies
The research team specializes in evaluating durvalumab-based regimens for patients with Stage IIA to IIIB non-small cell lung cancer, encompassing both squamous and non-squamous histologies. Their work emphasizes improving event-free survival through integrated neoadjuvant and adjuvant treatment strategies that bridge the gap between medical oncology and thoracic surgery.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 26 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in LKH Feldkirch Intern E at LKH Rankweil
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Olaparib Monotherapy and Olaparib-Durvalumab Combination in Neoadjuvant Treatment of HER2-Negative BRCA-Mutated Breast Cancer | AstraZeneca AB | Phase II | Not Recruiting | Oct 2022 | Sep 2025 |
IMP list
lock Showing 1 of 26 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 3 | Unknown | 2019-02-21 | 2025-03-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.